175203-55-1

Basic information

• Product Name: ETHYL 4-(PROP-2-YNYLOXY)BENZOATE
• Synonyms: ETHYL 4-(PROP-2-YNYLOXY)BENZOATE;3-(4-ETHOXYCARBONYLPHENOXY)PROP-1-YNE
• CAS NO: 175203-55-1
• Molecular Formula: C₁₂H₁₂O₃
• Molecular Weight: 204.22188
• Mol File: 175203-55-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 314.1°C at 760 mmHg
• Flash Point: 128.5°C
• Appearance: /
• Density: 1.106g/cm³
• Vapor Pressure: 0.000476mmHg at 25°C
• Refractive Index: 1.523
• CAS DataBase Reference: ETHYL 4-(PROP-2-YNYLOXY)BENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 4-(PROP-2-YNYLOXY)BENZOATE(175203-55-1)
• EPA Substance Registry System: ETHYL 4-(PROP-2-YNYLOXY)BENZOATE(175203-55-1)

Safety Data

• Hazardous Substances Data: 175203-55-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H12O3/c1-3-9-15-11-7-5-10(6-8-11)12(13)14-4-2/h1,5-8H,4,9H2,2H3

Upstream product

• 120-47-8 Ethyl 4-hydroxybenzoate 
• 106-96-7 propargyl bromide 

Downstream Products

• 120-47-8 Ethyl 4-hydroxybenzoate 
• 1190113-92-8 C₃₆H₃₆O₉ 
• 1190113-80-4 C₃₆H₃₆O₉ 
• 34905-02-7 [4-(prop-2-yn-1-yloxy)phenyl]methanol 
• 1551218-04-2 C₂₁H₁₆BrN₅O₅ 
• 1417919-52-8 ethyl para-((hexacarbonyldicobalt)propargyloxy)benzoate 
• 1384484-64-3 diethyl 4,4'-(2,4-hexadiyne-1,6-diylbis(oxy))dibenzoate 
• 1393750-82-7 C₃₀H₃₄F₂N₄O₁₂ 
• 1351982-04-1 4-((1-((4-amino-2-methylpyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)methoxy)benzoic acid 
• 1351982-03-0 ethyl 4-((1-((4-amino-2-methylpyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)methoxy)benzoate 
• 1196658-74-8 1-(3,4,6-tri-O-acetyl-1,5-anhydro-2-deoxy-D-galactitol-2-yl)-4-(4-ethoxycarbonylphenoxy)methyl-1,2,3-triazole 
• 21926-55-6 4-(prop-2-ynyloxy)benzoic acid 
• 935692-95-8 4-{3-[6-(4-methoxy-phenyl)-pyridazin-3-yl]-prop-2-ynyloxy}-benzoic acid ethyl ester 

Relevant articles and documents

A new NT4 peptide-based drug delivery system for cancer treatment

The development of selective tumor targeting agents to deliver multiple units of chemotherapy drugs to cancer tissue would improve treatment efficacy and greatly advance progress in cancer therapy. Here we report a new drug delivery system based on a tetr

Synthesis and biological evaluation of 4-(1,2,3-triazol-1-yl)coumarin derivatives as potential antitumor agents

In this research, a series of 4-(1,2,3-triazol-1-yl)coumarin conjugates were synthesized and their anticancer activities were evaluated in vitro against three human cancer cell lines, including human breast carcinoma MCF-7 cell, colon carcinoma SW480 cell and lung carcinoma A549 cell. To increase the biological potency, structural optimization campaign was conducted focusing on the C-4 position of 1,2,3-triazole and the C-6, C-7 positions of coumarin. In addition, to further evaluate the role of 1,2,3-triazole and coumarin for antiproliferative activity, 9 compounds possessing 4-(piperazin-1-yl)coumarin framework and 3 derivatives baring quinoline core were also synthesized. By MTT assay in vitro, most of the compounds display attractive antitumor activities, especially 23. Further flow cytometry assays demonstrate that compound 23 exerts the antiproliferative role through arresting G2/M cell-cycle and inducing apoptosis.

Hybrid system of metal/Bronsted acid relay catalysis for the intramolecular double hydroarylation and cationic cyclization of diyne diethers and diamines

We have developed a hybrid system of metal/Bronsted acid relay catalysis for the intramolecular double hydroarylation and cationic cyclization of diyne diethers and diamines to give 4,4′-bi(2H-chromene), bi(2H-quinoline), and dioxafluoranthenes starting f